Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07116616 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 166 → 190 participants
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: details revised at 2 of 11 entries
  2. Site details revised at 1 of 10 sitesv9
  3. Site details revised at 2 of 10 sitesv8
  4. Site details revised at 1 of 10 sitesv7
  5. Site details revised at 1 of 10 sitesv6
Show 4 earlier versionsHide 4 earlier versions
  1. Site details revised at 1 of 10 sitesv5
  2. Site details revised at 2 of 10 sitesv4
  3. Site details revised at 1 of 10 sitesv3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 15, 2025 to Sep 30, 2025
    • Site details revised at 10 of 10 sites
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Moderna
49 trials monitored
See 3 trials at risk
Multiple Myeloma
1,261 trials monitored
See 80 trials at risk
The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM).
Trial Details
NCT Number NCT07116616
Lead Sponsor ModernaTX, Inc.
Conditions
(from sponsor)		 Relapsed or Refractory Multiple Myeloma
Related terms Multiple Myeloma, Recurrence
Enrollment 190 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov